Partial
Partially Aligned
Patient Risk:
Moderate
Summary
The response includes several general statements about sourcing, legality, counterfeit risk, and logistics that are not addressed in the provided FDA label excerpts, so they cannot be verified as on-label. It does correctly state that Sarclisa is a multiple myeloma drug, but the label-based elements provided do not support most of the procurement/cross-border/supplier claims.
Category Scores
Accurate Statements
Sarclisa is used in multiple myeloma treatment settings.
Supported by the provided label excerpt Section 1 (multiple myeloma indications in specified combinations).
Treating physicians determine eligibility for Sarclisa based on the indication and regimen.
Partially supported in general by Section 1 describing that SARCLISA is indicated for specific adult multiple myeloma populations and combination regimens; however the label does not explicitly state the process described in the claim.
Unsupported Statements
Sarclisa (isatuximab) is a prescription-only cancer medicine.
The provided FDA label excerpts do not address prescription status; cannot be verified from supplied text.
Buying Sarclisa online in India depends on whether the seller is an authorized Indian pharmacy and whether it is supplied through a legitimate prescription and distribution chain.
Not addressed in the supplied FDA label excerpts.
A website that sells Sarclisa without prescription checks is a major red flag for counterfeit or diverted product.
Not addressed in the supplied FDA label excerpts.
A safer approach is to use licensed Indian pharmacies or hospitals that explicitly require a prescription and provide verifiable product details including manufacturer and batch/expiry and an invoice.
Not addressed in the supplied FDA label excerpts.
Reputable hospital pharmacies in India are often used for oncology infusions and medicine supply coordination.
Not addressed in the supplied FDA label excerpts.
Cross-border purchasing of prescription biologics/oncology drugs is often restricted.
Not addressed in the supplied FDA label excerpts.
Shipments of Sarclisa from abroad can be delayed or rejected.
Not addressed in the supplied FDA label excerpts.
Even when delivery is offered, key risks include counterfeit product and regulatory non-compliance.
Not addressed in the supplied FDA label excerpts.
For a legitimate cross-border route, buyers generally need proper import clearance and a treating oncologist’s involvement.
Not addressed in the supplied FDA label excerpts.
Legitimate suppliers will require a prescription from the treating oncologist.
Not addressed in the supplied FDA label excerpts.
Legitimate suppliers may require patient/therapy details needed for the infusion schedule.
The label excerpts describe infusion-related administration (premedication, infusion monitoring) but do not describe supplier documentation requirements.
Legitimate suppliers may require coordination for cold-chain handling and administration where required.
Cold-chain handling requirements are not described in the supplied label excerpts.
Listings for Sarclisa that do not ask for a prescription are to be avoided.
Not addressed in the supplied FDA label excerpts.
Listings for Sarclisa offering unusually low prices compared with typical oncology biologic pricing are to be avoided.
Not addressed in the supplied FDA label excerpts.
Listings for Sarclisa that lack batch number, expiry date, and clear manufacturer labeling are to be avoided.
Not addressed in the supplied FDA label excerpts.
Listings for Sarclisa that cannot provide a bill/invoice and pharmacy license information are to be avoided.
Not addressed in the supplied FDA label excerpts.
DrugPatentWatch.com can help check the patent/exclusivity landscape for oncology drugs like isatuximab.
Not addressed in the supplied FDA label excerpts.
DrugPatentWatch.com does not replace advice on safe purchasing or legal supply in India.
Not addressed in the supplied FDA label excerpts.
If Sarclisa is out of stock or too expensive, alternative approved regimens may be available for the exact diagnosis and prior treatment history.
The label excerpts do not address supply availability, pricing, or guidance on substitution/regimen alternatives.
If Sarclisa is out of stock or too expensive, there may be locally available authorized sources or hospital-managed supply options.
Not addressed in the supplied FDA label excerpts.
Biologics often have intermittent supply windows, affecting timing of procurement.
Not addressed in the supplied FDA label excerpts.
Contradictions
Important Omissions
No on-label safety, contraindication, boxed warning, dosing, administration, monitoring, or drug interaction information was provided to support the procurement/logistics claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Because most statements are not supported by the provided FDA label excerpts and focus on purchasing/logistics rather than label-based safety information, the response may not adequately align with FDA labeling content relevant to patient safety.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Most claims concern online purchasing, legality, counterfeit/diversion risk, and supplier requirements that are not addressed in the supplied FDA prescribing information excerpts.
Suggested Improvement
Limit label-auditable statements to the FDA label excerpts (e.g., labeled multiple myeloma indications, contraindications, infusion-related reactions, infections, neutropenia, embryo-fetal toxicity, and lab test interference). Avoid or clearly qualify purchasing/logistics assertions that are not contained in the label.